IL196867A0 - Titration schedule for bifeprunox for treating schizophrenia and kits for use therein - Google Patents

Titration schedule for bifeprunox for treating schizophrenia and kits for use therein

Info

Publication number
IL196867A0
IL196867A0 IL196867A IL19686709A IL196867A0 IL 196867 A0 IL196867 A0 IL 196867A0 IL 196867 A IL196867 A IL 196867A IL 19686709 A IL19686709 A IL 19686709A IL 196867 A0 IL196867 A0 IL 196867A0
Authority
IL
Israel
Prior art keywords
bifeprunox
kits
treating schizophrenia
titration schedule
titration
Prior art date
Application number
IL196867A
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of IL196867A0 publication Critical patent/IL196867A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL196867A 2006-08-31 2009-02-03 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein IL196867A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84124406P 2006-08-31 2006-08-31
EP06119936 2006-08-31
US84149506P 2006-09-01 2006-09-01
EP06120016 2006-09-01
PCT/EP2007/058957 WO2008025780A1 (en) 2006-08-31 2007-08-29 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein

Publications (1)

Publication Number Publication Date
IL196867A0 true IL196867A0 (en) 2009-11-18

Family

ID=38704953

Family Applications (1)

Application Number Title Priority Date Filing Date
IL196867A IL196867A0 (en) 2006-08-31 2009-02-03 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein

Country Status (10)

Country Link
EP (2) EP2059244A1 (en)
JP (2) JP2010501625A (en)
KR (1) KR20090063228A (en)
AU (2) AU2007291234A1 (en)
BR (1) BRPI0715445A2 (en)
CA (2) CA2661800A1 (en)
EA (1) EA200970239A1 (en)
IL (1) IL196867A0 (en)
NO (1) NO20091243L (en)
WO (2) WO2008025781A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060742A1 (en) * 2008-11-03 2010-06-03 Solvay Pharmaceuticals B.V. Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
WO2010070061A1 (en) * 2008-12-19 2010-06-24 Abbott Healthcare Products B.V. Compositions, kits and methods of a titration schedule for bifeprunox compounds
PL2445502T5 (en) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
JP7384812B2 (en) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド Aripiprazole dosing strategy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9708389B8 (en) * 1996-03-29 2015-12-08 Duphar Int Res piperazine and piperidine compounds, pharmaceutical compositions.
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
AR034206A1 (en) 2001-02-16 2004-02-04 Solvay Pharm Bv A PROCEDURE FOR THE PREPARATION OF MESILATES OF PIPERAZINE DERIVATIVES AND SUCH MESILATES
AR045362A1 (en) 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
RU2394821C2 (en) 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-oxides as prodrug of piperazine and piperidine derivatives

Also Published As

Publication number Publication date
EP2059245A1 (en) 2009-05-20
EP2059244A1 (en) 2009-05-20
NO20091243L (en) 2009-03-25
WO2008025781A1 (en) 2008-03-06
BRPI0715445A2 (en) 2014-05-13
KR20090063228A (en) 2009-06-17
JP2010501626A (en) 2010-01-21
WO2008025780A1 (en) 2008-03-06
CA2661120A1 (en) 2008-03-06
AU2007291234A1 (en) 2008-03-06
EA200970239A1 (en) 2009-08-28
JP2010501625A (en) 2010-01-21
AU2007291235A1 (en) 2008-03-06
CA2661800A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
IL193014A0 (en) Methods and compositions for treating schizophrenia
EP2175724A4 (en) Methods and compositions for treating schizophrenia using antipsychotic combination therapy
EP2004630A4 (en) 2-aminopyrimidin-4-ones and their use for treating or preventing a -related pathologies
BR112012006644A2 (en) compound, method of treating a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder or a neuronal disorder, pharmaceutical composition, use of a compound and kit
IL200889A0 (en) Compositions and kits for treating influenza
PL2271218T3 (en) Use and composition for treating dementia
GB0816413D0 (en) Purification method and kits
EP2034841A4 (en) Methods and compositions for treating biofilms
IL196867A0 (en) Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
ATE465229T1 (en) TEXTILE TREATMENT METHOD AND COMPOSITION
EP2078522A4 (en) Composition for treating allergy
HRP20130092T1 (en) Carbamoyl-cyclohexanes for treating acute mania
IL192745A0 (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
IL193697A0 (en) Methods for treating cognitive and other disorders
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
EP2013402A4 (en) Dryer and method of controlling for the same
EP2013405A4 (en) Dryer and method for controlling of the same
GB0718918D0 (en) Compositions and methods for treating skin conditions
GB0620930D0 (en) Composition and method for use thereof
GB0602449D0 (en) Chuck and method
EP1993612A4 (en) Compositions and methods for treating cognitive disorders
ZA200805398B (en) Use of kcnq-openers for treating or reducing the symptons of schizophrenia
GB0709579D0 (en) Composition and method for the assay and treatment of anthrax
GB0608354D0 (en) Composition and method for the assay and treatment of anthrax
AU2006906080A0 (en) A method and composition for treating the scalp